{"preliminary_commentary":{"by_channel":{"x_thread":3,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["tazemetostat","rituximab"]],"indication":"relapsed/refractory follicular lymphoma","name":"SYMPHONY-2","nct_id":"NCT04762160","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=symphony-2-nct04762160. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Tazemetostat 800 mg BID is administered daily starting on Cycle 1 Day 1 (C1D1). Tazemetostat will be administered from C1D1 to the end of Cycle 24, for 24 months of therapy or until disease progression, unacceptable toxicity, or withdrawal of consent. Rituximab will be administered by either subcutaneous injection or IV infusion according to the regional product prescribing information, labeling and institutional guidelines. Rituximab will be administered at a dose of 375 mg/m2 on Day 1, 8, 15, and 22 of Cycle 1, and then on Day 1 of Cycles 3 through 6, accounting for an additional 4 doses, i.e., a total of 8 doses of rituximab in 6 cycles.","label":"Tazmetostat in combination with rituximab","type":"EXPERIMENTAL"}],"collaborators":["Swedish Cancer Institute"],"completion_date":{"date":"2022-03-22","type":"ACTUAL"},"conditions":["Follicular Lymphoma"],"enrollment":{"count":5,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Tazemetostat","otherNames":["EPZ-6438"],"type":"DRUG"},{"name":"Rituximab","otherNames":["Rituximab Hyaluronidase"],"type":"COMBINATION_PRODUCT"}],"last_update":"2024-03-25","lead_sponsor":"Epizyme, Inc.","official_title":"SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-03-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"Planned to be assessed during Cycles 3, 6, 12, 18, and 24."}],"references":[],"start_date":{"date":"2020-12-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma","url":"https://clinicaltrials.gov/study/NCT04762160"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/symphony-2-nct04762160"}